Novo Nordisk (NVO)
(Delayed Data from NYSE)
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$136.97 USD
+0.09 (0.07%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $136.93 -0.04 (-0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth D Momentum C VGM
Zacks News
Allergan (AGN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
While Allergan's (AGN) Q4 sales are likely to be driven by new as well as established products like Botox and international growth, generic competition for some key products will hurt sales.
Novo Nordisk (NVO) Misses Q4 Earnings Estimates, Sales Beat
by Zacks Equity Research
Novo Nordisk's (NVO) top-line growth was backed by growth in new-generation insulin, Victoza, Saxenda, and haemophilia products.
Can Merck (MRK) Deliver a Positive Surprise in Q4 Earnings?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda and Bridion are likely to drive sales in the fourth quarter. However, headwinds remain in the form of genericization of key drugs and increasing competition.
Company News For Jan 30, 2018
by Zacks Equity Research
Companies In The News are: LMT,DPS,CYOU,ABLYF,SNY,NVO
Sanofi on a Buyout Spree This Month, to Buy Ablynx for $4.8B
by Zacks Equity Research
Sanofi (SNY) to acquire Ablynx for EUR 3.9 billion to expand its late stage pipeline and strengthen rare blood disorder growth platform.
Why Novo Nordisk (NVO) Might Surprise This Earnings Season
by Zacks Equity Research
Novo Nordisk (NVO) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
AbbVie (ABBV) Soars on Q4 Results: Key Takeaways from the Earnings Call
by Arpita Dutt
With AbbVie (ABBV) surpassing expectations in the fourth quarter, here's a look at a few important takeaways from the company's conference call.
AbbVie (ABBV) Q4 Earnings Beat, 2018 View Raised, Shares Up
by Zacks Equity Research
AbbVie's (ABBV) Q4 earnings top estimates with revenues marginally beating the same. Sales of the company's lead marketed drug, Humira, also rise year over year.
Biotech M&A Off to a Strong Start in 2018: More Deals to Follow?
by Arpita Dutt
Does Celgene's (CELG) decision to acquire Juno signal the revival of biotech M&A activity after a slow 2017?
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, AbbVie, Amgen, Novo-Nordisk and Zoetis
Can These 4 Large-Cap Drug Stocks Deliver an Encore in '18?
by Zacks Equity Research
We present four large cap drug companies, which are expected to repeat their last year's industry beating performance in 2018.
Novo Nordisk's (NVO) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Regulatory approvals of some key pipeline candidates along with the strong performance of products like Victoza have contributed to a rally in Novo Nordisk's (NVO) shares.
Teva's Trisenox Gets FDA Approval as First-Line Treatment
by Zacks Equity Research
Teva Pharmaceutical (TEVA) receives approval from the FDA for label expansion of its leukemia drug, Trisenox, in first-line setting.
Foreign Stock Roundup: Infosys Beats; AstraZeneca's Asthma Drug Gets Approval in EU
by Swarup Gupta
Global markets endured a volatile week, guided by opposing factors.
Why is Novo Nordisk Stock Up More Than 50% in Past Year?
by Zacks Equity Research
We take a look at the factors that led to the rise in Novo Nordisk's (NVO) share price in the past year.
Novo Nordisk's Ozempic Gets Canadian Approval for Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) announced that Health Canada has approved Ozempic to improve glycemic control in adults with type II diabetes mellitus.
Novo Nordisk Confirms Bid for Ablynx But Faces Rejection
by Zacks Equity Research
Novo Nordisk (NVO) confirmed its revised offer made on Dec 22, to acquire Ablynx NV for $3.1 billion.
3 Large-Cap Pharma Stocks to Watch Out for This New Year
by Zacks Equity Research
We take a look at a few Large Cap drug stocks with a favorable combination of Zacks Rank and VGM Score. The stocks are poised to carry on their bull run this year too.
Orexigen Struggles as Contrave Commercialization Costs Rise
by Zacks Equity Research
Orexigen (OREX) hurt by higher commercialization costs related to Contrave.
5 Reasons to Invest in Novo Nordisk (NVO) Stock Right Now
by Zacks Equity Research
Let's take a look at few factors that help in determining if Novo Nordisk (NVO) will be a good investment in 2018.
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson and Johnson, AbbVie, Roche's, AstraZeneca and Novo-Nordisk A/S
4 Large-Cap Pharma Stocks That Outperformed the S&P This Year
by Zacks Equity Research
We take a look at a few Large Cap stocks, which have surpassed the S&P 500 index in 2017 due to upsides on both regulatory and pipeline fronts.
Novo Nordisk's (NVO) Semaglutide Gets Positive CHMP Opinion
by Zacks Equity Research
Novo Nordisk (NVO) announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion recommending marketing authorisation of semaglutide for the treatment of adults with type II diabetes mellitus.
Lilly Issues Guidance for 2018, New Drugs to Drive Top Line
by Zacks Equity Research
Eli Lilly (LLY) issues financial guidance for 2018 and also reaffirms the previously issued 2017 projection as well as its long-term expectations.
Novo Nordisk's Semaglutide Gets FDA Approval for Diabetes
by Zacks Equity Research
Novo Nordisk (NVO) announced that the FDA approved semaglutide, which is a once-weekly injection approved to improve glycaemic control in adults with type II diabetes mellitus.